Treatment of PD-1 Inhibitor in AIDS-associated PML
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
PD-1 inhibitor ļ¼Pembrolizumab, 2mg/kg weight, once per 4 weeks and 3 times of medication
usageļ¼treatment on AIDS patients with progressive multifocal leukoencephalopathy.